Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.
Allogeneic stem cell transplantation (SCT) for solid tumors remains under investigation. We report a case of extended disease stability after a nonmyeloablative peripheral blood SCT for metastatic, refractory Ewing sarcoma. Of note, the patient developed metastatic disease to 2 unusual sites-the brain and small intestine. The allogeneic SCT environment may alter typical metastatic patterns, and may represent an ideal platform to manipulate and enhance the antitumor immune response. Further clinical trials are needed to evaluate the role for allogeneic SCT for this disease.
Capitini
Christian M
CM
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. capitinic@mail.nih.gov
Derdak
Joanne
J
Hughes
Marybeth S
MS
Love
Cynthia P
CP
Baird
Kristin
K
Mackall
Crystal L
CL
Fry
Terry J
TJ
D000328:Adult; D001932:Brain Neoplasms / Q000556:secondary; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007414:Intestinal Neoplasms / Q000556:secondary; D008297:Male; D009362:Neoplasm Metastasis / Q000473:pathology*; D012512:Sarcoma, Ewing / Q000473:pathology*; D014184:Transplantation, Homologous; D017211:Treatment Failure